IDT Biologika filled the second clinical batch of a newly-developed vaccine candidate against the coronavirus SARS-CoV-2 in Dessau. Now, around 1,000 individual vaccine doses with the highest intended dosage level are to be inspected, tested in quality control, labelled and packed before being sent to Hamburg. There, the study of clinical phase 1 will begin at Universitätsklinikum Eppendorf (UKE), with the presentation of all official approvals and the agreement of the ethics commission. In a to...